The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
POWER: An open-label, randomized phase III trial of cisplatin and 5-FU with or without panitumumab (P) for patients (pts) with nonresectable, advanced, or metastatic esophageal squamous cell cancer (ESCC).
Markus Hermann Moehler
Honoraria - Amgen
Ingo Ringshausen
No relevant relationships to disclose
Ralf Hofheinz
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Research Funding - Amgen
Salah-Eddin Al-Batran
No relevant relationships to disclose
Lothar Mueller
No relevant relationships to disclose
Peter C. Thuss-Patience
No relevant relationships to disclose
Kersten Borchert
No relevant relationships to disclose
Aysun Karatas
No relevant relationships to disclose
Ralph Keller
No relevant relationships to disclose
Anja Klein
No relevant relationships to disclose
Anne Kranich
No relevant relationships to disclose
Baruch Brenner
Consultant or Advisory Role - Amgen
Sylvie Lorenzen
No relevant relationships to disclose
Manfred P. Lutz
No relevant relationships to disclose
Richard Greil
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Research Funding - Amgen
Josep Tabernero
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Eric Van Cutsem
No relevant relationships to disclose
Ullrich Graeven
Consultant or Advisory Role - Amgen